{"entity":{"id":"io-biotech","kind":"company","name":"IO Biotech","aka":[],"tldr":"IO Biotech makes an off-the-shelf cancer vaccine that trains T cells to attack both tumour cells and the immune-suppressing cells around them. Its large melanoma trial narrowly missed its main goal in 2025 and the company is now reviewing its options.","summary":"IO Biotech (Nasdaq: IOBT), headquartered in Copenhagen with a US office in New York, develops immune-modulatory cancer vaccines on its T-win platform. Lead candidate Cylembio (IO102-IO103) stimulates T cells against indoleamine 2,3-dioxygenase 1 (IDO1) positive and PD-L1 positive cells, aiming to kill both tumour cells and immune-suppressive cells in the tumour microenvironment. In the phase 3 IOB-013 trial in first-line advanced melanoma, Cylembio plus pembrolizumab gave median progression-free survival of 19.4 months versus 11.0 months for pembrolizumab alone (hazard ratio 0.77, 95 percent CI 0.58 to 1.00, p=0.0558), narrowly missing the prespecified significance threshold of p≤0.045 (ESMO, October 2025). Five-year outcomes from the phase 1/2 trial were published in Nature Communications in December 2025. In January 2026 the company engaged Raymond James to explore strategic alternatives and announced a workforce reduction to preserve cash.","asOf":"2026-09-10","links":[{"label":"Official website","url":"https://www.iobiotech.com"},{"label":"Phase 3 results for Cylembio plus pembrolizumab (ESMO 2025)","url":"https://www.globenewswire.com/news-release/2025/10/20/3169094/0/en/io-biotech-presents-phase-3-results-for-cylembio-plus-keytruda-pembrolizumab-in-first-line-advanced-melanoma-at-esmo-2025.html"},{"label":"Corporate update and strategic alternatives (January 2026)","url":"https://www.globenewswire.com/news-release/2026/01/30/3229500/0/en/io-biotech-provides-corporate-update.html"}],"tags":[],"related":[],"cancers":["melanoma"],"sections":["immunotherapy"],"technologies":["shared-antigen-vaccine"],"targets":["pdl1"],"drugs":["io102-io103"],"companies":[],"institutions":[],"pathways":[],"terms":[],"trials":["nct05280314"],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":["No financing round could be sourced from fetched pages. Outcome of the strategic review after January 2026 not verified. Founding year not sourced."],"hq":"Copenhagen","country":"DK","companyType":"biotech","website":"https://www.iobiotech.com","ticker":"IOBT","stage":"public","investors":[],"funding":[]},"route":"/companies/io-biotech/","neighbours":{"cancer":[{"id":"melanoma","kind":"cancer","name":"Melanoma","route":"/cancers/melanoma/"}],"section":[{"id":"immunotherapy","kind":"section","name":"Immunotherapy","route":"/fronts/immunotherapy/"}],"technology":[{"id":"shared-antigen-vaccine","kind":"technology","name":"Off-the-shelf cancer vaccines","route":"/technologies/shared-antigen-vaccine/"}],"target":[{"id":"pdl1","kind":"target","name":"PD-L1","route":"/targets/pdl1/"}],"drug":[{"id":"io102-io103","kind":"drug","name":"IO102-IO103","route":"/drugs/io102-io103/"}],"trial":[{"id":"nct05155254","kind":"trial","name":"IO102-IO103 in Combination With Pembrolizumab Versus Pembrolizumab Alone in Advanced Melanoma (IOB-013 / KN-D18)","route":"/trials/nct05155254/"},{"id":"nct05280314","kind":"trial","name":"Phase II Trial of Neoadjuvant and Adjuvant IO102-IO103 and Pembrolizumab KEYTRUDA® in Patients With Resectable Tumors","route":"/trials/nct05280314/"}]}}